[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338411-105":59,"doc-detail-338411-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unraveling-the-cdk9pp2aerk-network-in-transcriptional-pause-release-and-complement-activation-in-kras-mutant-cancers","Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers","","Selective inhibition of the transcription elongation factor P-TEFb complex is promising for cancer therapy, yet CDK9 inhibitors (CDK9i) show limited performance in KRAS-mutant cancers beyond initial in vitro responses. Mechanistically, CDK9 inhibition triggers compensatory ERK-MYC activation, restores proto-oncogenes, induces immediate early genes, activates the complement C1r-C3-C3a cascade, and promotes tumor immunosuppression. The CDK9/Src-PP2Ac “paradoxical” regulation supports ERK phosphorylation and RNA polymerase II pause release. Co-targeting CDK9 with KRAS/MAPK signaling suppresses these feedback and improves control, with complement-driven tumor microenvironment modulation further enhancing efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unraveling-the-cdk9pp2aerk-network-in-transcriptional-pause-release-and-complement-activation-in-kras-mutant-cancers/338411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unraveling-the-cdk9pp2aerk-network-in-transcriptional-pause-release-and-complement-activation-in-kras-mutant-cancers/338411.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic rationale for targeting the CDK9/P-TEFb complex?","Question",{"text":112,"@type":113},"P-TEFb (containing CDK9) regulates RNA polymerase II pause release and supports transcription elongation of signal-responsive genes, making CDK9 inhibition a potential cancer therapy approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are CDK9 inhibitors less effective in vivo for KRAS-mutant cancers?",{"text":117,"@type":113},"Despite in vitro responses, CDK9 inhibition triggers compensatory signaling, including ERK-MYC activation, recovery of proto-oncogenes, induction of immediate early genes, and complement-driven tumor immunosuppression in nude mouse xenograft models.",{"name":119,"@type":110,"acceptedAnswer":120},"How does co-targeting CDK9 and KRAS/MAPK pathways improve outcomes?",{"text":121,"@type":113},"Co-targeting eliminates ERK-MYC activation and prevents feedback activation mediated by receptor tyrosine kinases, leading to more effective control of KRAS-mutant cancers and overcoming KRAS inhibitor resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338411,1790146235,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nUnraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers  \nYafang Wang, Lansong Xu, Lijun Ling, Mingyue Yao, Shangxuan Shi, Chengcheng Yu, Yingnian Li, Jie Shen, Hualiang Jiang, and Chengying Xie*  \nSelective inhibition of the transcription elongation factor (P-TEFb) complex represents a promising approach in cancer therapy, yet CDK9 inhibitors (CDK9i) are currently limited primarily to certain hematological malignancies. Herein, while initial responses to CDK9-targeted therapies are observed in vitro across various KRAS-mutant cancer types, their eﬃcacy is far from satisfactory in nude mouse xenograft models. Mechanistically, CDK9 inhibition leads to compensatory activation of ERK-MYC signaling, accompanied by the recovery of proto-oncogenes, upregulation of immediate early genes (IEGs), stimulation of the complement C1r-C3-C3a cascade, and induction of tumor immunosuppression. The “paradoxical” regulation of PP2Ac activity involving the CDK9/Src interplay contributes to ERKphosphorylation and pause-release of RNA polymerase II (Pol II). Co-targeting ofCDK9 and KRAS/MAPK signaling pathways eliminates ERK-MYC activation and prevents feedback activation mediated by receptor tyrosine kinases, leading to more eﬀective control ofKRAS-mutant cancers and overcoming KRASi resistance. Moreover, modulating the tumor microenvironment (TME) by complement system intervention enhances the response to CDK9i and potently suppresses tumor growth. Overall, the preclinical investigations establish a robust framework for conducting clinical trials employing KRASi/SOS1i/MEKi or immunomodiﬁers in combination with CDK9i to simultaneously target cancer cells and their crosstalk with the TME, thereby yielding improved responses in KRAS-mutant patients.  \n1. Introduction  \nSince the identiﬁcation of oncogenes encoding protein kinases, optimism surrounding kinase inhibition as a targeted therapeutic strategy has now translated into clinical reality, including cyclin-dependent kinases (CDKs), particularly the approved CDK4/6 inhibitors and ongoing clinical trials for other CDKs. [1] Among these, CDK9, the catalytic subunit of positive transcription elongation factor b (P-TEFb), facilitates the pause-release of RNA polymerase II (Pol II) and reinforces the transcriptional elongation of signal-responsive genes. [2] Acute inhibition of CDK9 leads to transient suppression of transcription and preferential depletion of short-lived proteins such as Mcl-1[3] and c-Myc. [4] Therefore, CDK9 inhibitors (CDK9i) have demonstrated therapeutic eﬃcacy in preclinical models of Mcl-1- or MYC-driven malignancies, leading to their advancement into clinical trials. Although CDK9i have shown potent cytotoxicity against solid tumor cells in vitro studies, intrinsic resistance dominatesin in vivo models. The US Food and Drug Administration (FDA) approval remains elusive due to potency and speciﬁcity  \nY. Wang, L. Xu, L. Ling, M. Yao, S. Shi, H. Jiang, C. Xie Shanghai Institute for Advanced Immunochemical Studies ShanghaiTech University  \n393 Middle Huaxia Road, Shanghai 201210, P. R. China  \nE-mail: [xiecy@lglab.ac.cn](xiecy@lglab.ac.cn)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202404926](https://doi.org/10.1002/advs.202404926)[ ](https://doi.org/10.1002/advs.202404926)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202404926  \nL. Xu, M. Yao  \nThe First Aﬃliated Hospital of USTC (Anhui Provincial Hospital) Division of Life Sciences and Medicine  \nUniversity of Science and Technology of China Hefei, Anhui 230026, P. R. China  \nM.","cbCait3FGZkV59zi","https://ap.wps.com/l/cbCait3FGZkV59zi","pdf",10111832,"English","# Introduction\n## CDK9 inhibition and limitations\n## KRAS mutations and therapeutic challenges","[{\"question\":\"What is the main therapeutic rationale for targeting the CDK9/P-TEFb complex?\",\"answer\":\"P-TEFb (containing CDK9) regulates RNA polymerase II pause release and supports transcription elongation of signal-responsive genes, making CDK9 inhibition a potential cancer therapy approach.\"},{\"question\":\"Why are CDK9 inhibitors less effective in vivo for KRAS-mutant cancers?\",\"answer\":\"Despite in vitro responses, CDK9 inhibition triggers compensatory signaling, including ERK-MYC activation, recovery of proto-oncogenes, induction of immediate early genes, and complement-driven tumor immunosuppression in nude mouse xenograft models.\"},{\"question\":\"How does co-targeting CDK9 and KRAS/MAPK pathways improve outcomes?\",\"answer\":\"Co-targeting eliminates ERK-MYC activation and prevents feedback activation mediated by receptor tyrosine kinases, leading to more effective control of KRAS-mutant cancers and overcoming KRAS inhibitor resistance.\"}]","Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers | PDF",1790023537,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e268e6b7b963c903ec7b8e78c156a0ce.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a37f25131a19a5a1602846cc3f31e8a0.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fd15c5c067cc92295a8408ce1a65c04.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a93ea6218dbcb478d629a6f7d0179d4.webp",980,1287]